Motac Neuroscience

Motac Neuroscience operates a hybrid business model, combining a specialized preclinical CRO service with an internal drug discovery and development pipeline. Its core strength lies in its deep scientific expertise in neurodegenerative and psychiatric disorders, particularly Parkinson's disease, supported by state-of-the-art rodent and non-human primate (NHP) facilities and a team with extensive publication and discovery records. The company leverages its research services to fund and de-risk its own asset development, seeking strategic alliances to advance its proprietary programs targeting movement disorders.

Specialized in vivo and ex vivo preclinical model systems with high translational validity for CNS disorders, including state-of-the-art rodent and non-human primate (NHP) facilities. Expertise encompasses neuroanatomy, physiology, pharmacology, and psychology, supported by a network for clinical translation.

Competes with other specialty preclinical CROs (e.g., PsychoGenics, Charles River's specialized units) and broader, full-service CROs offering neuroscience capabilities. Differentiates through deep, publication-backed expertise in specific movement disorder models and a hybrid model that includes proprietary drug discovery.